Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245227 · ClinicalTrials.gov registry record · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
A Phase 3 study of Postpartum Hemorrhage, sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,358
- Enrollment target
- 1
- Study location
NCT05245227 is a Phase 3 study of Postpartum Hemorrhage that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 1,358 participants, above the 81-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (1577% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05245227, a Phase 3 study of Postpartum Hemorrhage, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,358 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage. Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).
Conditions Studied
Interventions
- DRUG Sublingual Misoprostol
- DRUG IV Oxytocin
Study Locations (1)
New York
- Stony Brook University - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,358 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05245227
The ClinicalTrials.gov registry entry for NCT05245227 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,358 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (1577% higher). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Sublingual Misoprostol is the first listed.
NCT05245227 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05245227 about?
NCT05245227 is a clinical study titled "Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage". To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: ...
What is the current status of trial NCT05245227?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,358 participants. The study started on 2025-01-27. Estimated completion is 2027-01-01.
What conditions does trial NCT05245227 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage.
What interventions are being tested in trial NCT05245227?
The interventions under investigation include: Sublingual Misoprostol (DRUG), IV Oxytocin (DRUG).
Who is sponsoring clinical trial NCT05245227?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245227 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
COMPLETED · Phase 3
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
COMPLETED · NA
-
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
COMPLETED · Phase 1
-
Prophylactic Methylergonovine for Twin Cesarean
COMPLETED · Phase 4
-
Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.